SANUWAVE Announces Record Q4 and FY2023 Revenue

Rhea-AI Summary

SANUWAVE Health, Inc. reports record revenues for Q4 2023 and FY 2023, with significant growth in operating income. The company provides strong revenue growth guidance for Q1 2024 and FY 2024. UltraMIST® systems and consumables drive revenue growth, with a focus on profitable expansion. Adjusted EBITDA shows notable improvement, reflecting operational efficiencies. The company aims for rapid, profitable growth in the upcoming year, expecting substantial revenue increases.

Positive

• Record revenues of $7.0 million for Q4 2023, a 27% increase from Q4 2022
• FY 2023 revenues hit a record $20.4 million, up 22% from FY 2022
• Operating income of $1 million for Q4 2023, compared to a loss of $1.5 million in Q4 2022
• Guidance for 45-55% revenue growth in Q1 2024 vs Q1 2023 and 50% growth in FY 2024 vs FY 2023
• UltraMIST® systems and consumables drive revenue growth, representing over 90% of revenues in Q4 2023
• Gross margin at 69.1% for Q4 2023, impacted by non-recurring inventory write-offs
• Net income of $18.2 million in Q4 2023, driven by fair value change of derivative liabilities
• Adjusted EBITDA of $0.7 million in Q4 2023, compared to a loss of $1.3 million in Q4 2022
• Annual revenue guidance for FY 2024 expects over 50% growth compared to FY 2023, targeting revenues of over $30 million
• Focus on profitable growth, operational efficiencies, and overcoming previous constraints for accelerated expansion

Negative

• None.

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022

FY 2023 revenues were a record $20.4 million, up 22% from FY2022

Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022

Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023

EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months and fiscal year ended December 31, 2023.

Q4 2023 ended December 31, 2023

• Revenue for the three months ended December 31, 2023 totaled $7.0 million, an increase of 27%, as compared to $5.5 million for the same period of 2022. This growth is slightly higher than previous guidance for a 20-24% increase.
• 79 UltraMIST® systems were sold in Q4 2023, up from 28 in Q1 2023, 49 in Q2 2023, and 55 in Q3 2023. In addition, 19 systems were placed into RTO (rent to own) contracts in Q4 2023.
• UltraMIST® consumables revenue increased by 21% to $3.6 million (51% of revenues) in Q4 2023, versus $3.0 million for the same quarter last year. UltraMIST systems and consumables remained the primary revenue growth driver and represented in excess of 90% of SANUWAVE’s overall revenues in Q4 2023.
• Gross margin as a percentage of revenue amounted to 69.1% for the three months ended December 31, 2023, vs. 78.1% for the same period last year, driven mainly by non-recurring inventory write-offs.
• For the three months ended December 31, 2023, operating income totaled $1.0 million, an improvement of $2.5 million compared to Q4 2022 as a result of the Company’s efforts to drive profitable growth and manage expenses during 2023.
• Net income for the fourth quarter of 2023 was $18.2 million, driven predominantly by the change in the fair value of derivative liabilities.
• Adjusted EBITDA ¹ for the three months ended December 31, 2023 was $0.7 million versus an Adjusted EBITDA loss of $1.3 million for the same period last year, an improvement of $2.0 million.
  
  [1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information.
  

Fiscal Year 2023 Highlights

• Revenue for FY 2023 ended December 31, 2023 totaled $20.4 million, an increase of 22% compared to $16.7 million for FY 2022.
• 211 UltraMIST® systems were sold and 19 more were placed into RTO in FY 2023.
• Gross margin as a percentage of revenue was 70.4% vs. 74.1% in the prior year. This decrease was primarily driven by non-recurring inventory write offs and supply constraints during the year.
• FY 2023 operating loss totaled $0.5 million, an improvement of $8.5 million compared to FY 2022 as a result of the Company’s efforts to drive profitable growth and manage expenses during 2023.
• Net loss was $25.8 million, compared to a net loss of $10.3 million for FY 2022. Net loss is mainly driven by non-cash losses on the fair value of derivative liabilities.
• Adjusted EBITDA loss for FY 2023 was $1.2 million versus an Adjusted EBITDA loss of $7.2 million for the same period last year, an improvement of $6.0 million reflecting improved operational efficiencies.

“After a couple of quarters spent addressing manufacturing and supply issues, bringing costs into line, and setting the Company up for growth, we are very pleased to state that we believe that the acceleration is here,” said Morgan Frank, CEO. “Q4 and FY 2023 as a whole were both records for the Company not just on revenue growth, but on operating profitability as well and we will continue to pursue our stated goal of rapid, profitable growth in the year to come and as our forward guidance in this press release indicates, we expect growth in 2024 to be markedly higher than in 2023 as we move past the operating constraints that have held us back and begin to realize the potential of the Company and of UltraMIST.”

Sanuwave recently launched its new website.

Please visit us at https://sanuwave.com and use the investor section to subscribe to future releases and news.

Financial Outlook

Sanuwave is initiating annual revenue guidance for the fiscal year ending December 31, 2024. The Company anticipates revenue growth of over 50% compared to FY 2023 with FY 2024 revenues expected to total over $30 million.

The Company also forecasts Q1 2024 revenue to rise 45-55% vs Q1 2023 and for gross margin as a percentage of revenue to increase back into the mid 70s.

Our merger with SEPA remains ongoing and active. Our financials went stale in February and so getting audited Q4 numbers out was important to being able to file the super 8-K for the business combination. We’re continuing to work toward finalizing exchange listing and hope to have more soon.

As previously announced, a business update will occur via conference call on March 22, 2024. Materials for the conference call at 8:30 a.m. EST are included on the Company website at www.sanuwave.com/investors.

Telephone access to the call will be available by dialing the following numbers:

Participant Listening: 1-800-267-6316 or 1-203-518-9783

OR click the link for instant telephone access to the event.

https://viavid.webcasts.com/starthere.jsp?ei=1661785&tp_key=8f8d9c1839

A replay will be made available through April 15, 2024:
Toll-Free: 1-844-512-2921 or 1-412-317-6671
Replay Access ID: 11155229

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Non-GAAP Financial Measures

This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (“U.S. GAAP”). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP. 

The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges.  EBITDA and Adjusted EBITDA should not be considered as alternatives to net loss as a measure of financial performance or any other performance measure derived in accordance with GAAP, and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to GAAP measures, allows them to see the Company’s results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other GAAP measures.

EBITDA and Adjusted EBITDA have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of these limitations are that EBITDA and Adjusted EBITDA:

• Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments.
• Do not reflect all changes in our working capital needs.
• Do not reflect interest expense, or the amount necessary to service our outstanding debt.
  

As presented in the GAAP to Non-GAAP Reconciliations section below, the Company’s non-GAAP financial measures exclude the impact of certain charges that contribute to our net loss.

Also note that the accompanying notes to consolidated financial statements are an integral part of these statements.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, the Company’s ability to consummate the proposed business combination with SEP Acquisition Corp. and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact : investors@sanuwave.com

SELECTED FINANCIAL DATA
FOR THE QUARTERS ENDED DECEMBER 31, 2023 AND 2022
(in thousands)			2023				2022
Revenue		$	6,994			$	5,500
Cost of revenues			2,159				1,190
Gross Margin			4,835				4,310
			69.1	%			78.4	%
Total operating expenses			3,796				5,773
Operating Income (Loss)		$	1,039			$	(1,463	)
Total other income (expense)			17,196				(4,234	)
Net Income (Loss)		$	18,235			$	(5,697	)
NON-GAAP ADJUSTED EBITDA
FOR THE QUARTERS ENDED DECEMBER 31, 2023 AND 2022
(in thousands)			2023				2022
Net Income (Loss)		$	18,235			$	(5,697	)
Non-GAAP Adjustments:
Interest expense			3,119				4,160
Depreciation and amortization			247				271
EBITDA			21,601				(1,266	)
Non-GAAP Adjustments for Adjusted EBITDA:
Change in fair value of derivative liabilities			(20,323	)			(57	)
Other non-cash or non-recurring charges:
Release of historical accrued expenses			(616	)			-
Adjusted EBITDA		$	662			$	(1,323	)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Years ended December 31, 2023 and 2022
(In thousands, except share and per share data)			2023				2022
Revenue		$	20,398			$	16,742
Cost of revenues			6,035				4,331
Gross Margin			14,363				12,411
Operating Expenses:
	General and administrative		8,674				12,556
	Selling and marketing		4,898				7,474
	Research and development		579				567
	Depreciation and amortization		752				766
Total Operating Expenses			14,903				21,363
Operating Loss			(540	)			(8,952	)
Other Income (Expense)
	Interest expense		(12,946	)			(12,771	)
	Interest expense, related party		(2,677	)			(1,361	)
	Change in fair value of derivative liabilities		(9,621	)			16,654
	Loss on issuance of debt		-				(3,434	)
	Loss on extinguishment of debt		-				(418	)
	Other expense		(19	)			(9	)
Total Other Expense			(25,263	)			(1,339	)
Net Loss Before Income Taxes			(25,803	)			(10,291	)
Income tax expense			4				2
Net Loss		$	(25,807	)		$	(10,293	)
Other Comprehensive Loss
	Foreign currency translation adjustments		(44	)			6
Total Comprehensive Loss		$	(25,851	)		$	(10,287	)
Loss per Share:
Net loss per share, basic and diluted		$	(0.03	)		$	(0.02	)
Weighted average shares outstanding, basic and diluted			793,850,994				549,470,787

Adjusted EBITDA		For the year ended
(in thousands)			2023				2022
Net income (loss)		$	(25,807	)		$	(10,293	)
Non-GAAP Adjustments:
Interest expense			15,623				14,132
Depreciation and amortization			1,028				952
EBITDA			(9,156	)			4,791
Non-GAAP Adjustments for Adjusted EBITDA:
Change in fair value of derivative liabilities			9,621				(16,654	)
Other non-cash or non-recurring charges:
Release of historical accrued expenses			(1,866	)			-
Shares issued for services			224				888
Loss on issuance of debt			-				3,434
Loss on extinguishment of debt			-				418
Adjusted EBITDA		$	(1,177	)		$	(7,123	)

CONSOLIDATED BALANCE SHEETS
December 31, 2023 and 2022
(In thousands, except share data)				2023				2022
ASSETS
Current Assets:
	Cash		$	1,797			$	1,153
	Accounts receivable, net of allowance of $1,237 and $1,037, respectively			3,314				4,029
	Inventory			2,951				868
	Prepaid expenses and other current assets			1,722				570
Total Current Assets				9,784				6,620
Non-Current Assets:
	Property, equipment and right of use assets, net			938				856
	Intangible assets, net			4,434				5,137
	Goodwill			7,260				7,260
Total Non-Current Assets				12,632				13,253
Total Assets			$	22,416			$	19,873
LIABILITIES
Current Liabilities:
	Senior secured debt, in default		$	18,278			$	14,416
	Convertible promissory notes payable			5,404				16,713
	Convertible promissory notes payable, related parties			1,705				7,409
	Asset-backed secured promissory notes payable			3,117				-
	Asset-backed secured promissory notes payable, related parties			1,458				-
	Accounts payable			5,705				4,400
	Accrued expenses			5,999				8,512
	Factoring liabilities			1,490				2,130
	Warrant liability			14,447				1,416
	Accrued interest			5,444				4,052
	Accrued interest, related parties			669				788
	Current portion of contract liabilities			92				60
	Other			947				319
Total Current Liabilities				64,755				60,215
Non-Current Liabilities:
	Lease liabilities			492				438
	Contract liabilities			347				230
Total Non-Current Liabilities				839				668
Total Liabilities			$	65,594			$	60,883
STOCKHOLDERS' DEFICIT
Preferred stock, par value $0.001, 5,000,000 shares authorized, 6,175 Series A, 293 Series B, 90 Series C, and 8 Series D designated shares, respectively; no shares issues and outstanding at 2023 and 2022			$	-			$	-
Common stock, par value $0.001, 2,500,000,000 shares authorized, 1,140,559,527 and 548,737,651 issued and outstanding at 2023 and 2022, respectively				1,140				549
Additional paid-in capital				175,842				152,750
Accumulated deficit				(220,049	)			(194,242	)
Accumulated other comprehensive loss				(111	)			(67	)
Total Stockholders' Deficit				(43,178	)			(41,010	)
Total Liabilities and Stockholders' Deficit			$	22,416			$	19,873

CONSOLIDATED STATEMENTS OF CASH FLOWS
Years ended December 31, 2023 and 2022
(In thousands)					2023				2022
Cash Flows - Operating Activities:
Net income (loss)				$	(25,807	)		$	(10,293	)
	Adjustments to reconcile net loss to net cash used by operating activities
		Depreciation and amortization			1,028				952
		Bad debt expense			781				253
		Shares issued for services			224				888
		Gain/loss on extinguishment of debt			-				418
		Income tax expense			4				2
		Change in fair value of derivative liabilities			9,621				(16,654	)
		Loss on issuance of debt			-				3,434
		Amortization of debt issuance and debt discounts			6,911				4,950
		Changes in operating assets and liabilities
			Accounts receivable		(53	)			(1,748	)
			Inventory, prepaid expenses and other assets		(3,006	)			(72	)
			Accounts payable		1,546				(2,550	)
			Accrued interest and accrued interest, related parties		6,306				3,182
			Accrued expenses and contract liabilities		(2,093	)			69
Net Cash Used by Operating Activities					(4,538	)			(17,169	)
Cash Flows - Investing Activities
	Proceeds of property and equipment				21				332
Net Cash Flows Provided by Investing Activities					21				332
Cash Flows - Financing Activities
	Proceeds from convertible promissory notes				3,026				16,227
	Proceeds from bridge notes payable				2,994
	Proceeds from senior secured promissory note				-				2,940
	Proceeds from factoring				(639	)			695
	Proceeds from warrant exercises				-				100
	Proceeds from short term borrowings				-				640
	Repayments of debt principal				-				(2,981	)
	Principal payments on finance leases				(170	)			(237	)
Net Cash Flows Provided by Financing Activities					5,211				17,384
Effect of Exchange Rates on Cash					(50	)			(13	)
Net Change in Cash During Period					644				534
Cash at Beginning of Period					1,153				619
Cash at End of Period				$	1,797			$	1,153
Supplemental Information:
	Cash paid for interest			$	1,958			$	3,712
Non-Cash Investing and Financing Activities:
	Warrants issued in conjunction with senior secured promissory note payable and
	convertible promissory notes payable			$	1,682			$	4,177
	Conversion of convertible notes payable and accrued interest to common stock				23,156				-
	Embedded conversion feature on convertible debt				835				2,760
	Common shares issued for advisory shares				302				-
	Settlement of debt and warrants with stock				-				1,361
	Common shares issued in conjunction with senior secured debt				-				3,720
	Warrant issuance in conjunction with convertible notes				-				1,708
	Reclassification of warrant liabilities to equity due to cashless warrant exercise				-				2,166
	Working capital balances refinanced into convertible notes payable				-				2,363

 

 

 

FAQ

What were SANUWAVE Health, Inc.'s record revenues for Q4 2023?

SANUWAVE Health, Inc. reported record revenues of $7.0 million for Q4 2023, a 27% increase from Q4 2022.

What was the revenue growth for FY 2023 compared to FY 2022?

FY 2023 revenues for SANUWAVE Health, Inc. totaled $20.4 million, up 22% from FY 2022.

What was the operating income for Q4 2023?

SANUWAVE Health, Inc. reported an operating income of $1 million for Q4 2023, a significant improvement from a loss of $1.5 million in Q4 2022.

What revenue growth is SANUWAVE Health, Inc. expecting for Q1 2024 and FY 2024?

The company provides guidance for 45-55% revenue growth in Q1 2024 compared to Q1 2023 and anticipates 50% revenue growth for FY 2024 compared to FY 2023.

What drove revenue growth for SANUWAVE Health, Inc. in Q4 2023?

UltraMIST® systems and consumables were the primary revenue growth drivers, representing over 90% of revenues in Q4 2023.